Core Viewpoint - The company, Chuangyue Huikang, is developing a comprehensive medical application service system centered around IoT technology, aiming to enhance healthcare services and operational management [2] Group 1: Company Developments - Chuangyue Huikang has established an intelligent IoT support platform that facilitates various medical application services, including convenience services, clinical application services, operational management services, and health services [2] - The company is creating IoT module products tailored to specific scenarios such as smart triage and appointment scheduling, with the goal of achieving comprehensive coverage of in-hospital medical scenarios [2] - The company commits to timely information disclosure regarding any business expansions in the future, encouraging stakeholders to pay attention to company announcements [2]

Core Viewpoint - The core investment theme for the pharmaceutical and biotechnology industry in 2025 is the internationalization of innovative drugs, with significant transactions boosting market confidence and new drug licensing revenues becoming a crucial funding source for sustainable corporate development [1] Group 1: Pharmaceutical and Biotechnology Industry - The internationalization of innovative drugs is expected to enhance corporate valuations, with China making continuous advancements in dual antibodies and ADCs, while also achieving breakthroughs in emerging technologies like small nucleic acids and inhalation formulations [1] - The proportion of overseas revenue in corporate value is anticipated to increase, as companies leverage their strengths in these areas [1] - The medical device sector is transitioning from low-value consumables to high-value consumables, overcoming certification and sales barriers, with high-value exports growing rapidly and the European and American markets becoming significant sources of incremental growth [1] Group 2: Market Dynamics - The impact of domestic centralized procurement is gradually being digested, leading to increased replacement opportunities, and the overall performance of the industry is expected to recover [1] - Domestic demand-driven segments, such as chain pharmacies and CROs, are undergoing a cleansing cycle, with leading companies gradually resuming growth [1] - The push for innovation and internationalization is driving the industry from low-level competition to source innovation, although structural opportunities should be monitored, as only truly innovative companies can share in the global market dividends [1] Group 3: Investment Instruments - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the medical device, medical services, and medical information sectors from the Shanghai and Shenzhen markets to reflect the overall performance of related securities in China's medical industry [1]

Core Viewpoint - The company, Yunzhisheng, has successfully secured a significant regional medical cooperation contract exceeding 20 million RMB, leveraging its advanced medical model technology and comprehensive service capabilities in the healthcare sector [1][2]. Group 1: Partnership and Financials - The total cooperation amount with Jiangsu Provincial Medical Insurance Bureau, Shijiazhuang Health Commission, and Jinshui District Health Commission in Zhengzhou exceeds 20 million RMB [1]. - This partnership highlights the company's technical strength and service capabilities in the field of medical digitalization [1]. Group 2: Technological Advancements - The collaboration signifies an evolution from single hospital cooperation to a comprehensive regional service, enhancing the application of medical models across the entire management system [1]. - The company's model services have progressed from application system output to core model capability output, providing deep technical support for the intelligent and refined upgrade of the medical insurance industry [1]. Group 3: Future Directions - The company aims to continue addressing traditional management inefficiencies in the healthcare system through technological empowerment, enhancing medical quality and safety control effectiveness [2]. - Future strategies include aligning with national policies, driving technological innovation, and expanding regional healthcare intelligent solutions to create greater industrial and social value [2].

在此背景下，思创医惠已加大物联网业务资源投入，集中全公司力量深耕该领域。2025年4月，公司与 浙江省温州市苍南县人民政府签署《战略合作框架协议》，聚焦RFID（无线射频识别）技术落地与苍 南本土产业的深度融合；与此同时，公司通过此前的资产出售回笼相关资金，用于补充流动资金及加码 物联网业务。 对于拟变更的新证券简称，上述负责人解读称，"思创"延续公司长期使用的核心品牌标识，"智联"则精 准概括公司核心发展方向，直接对应公司"商业智能、物联网"的主营业务，彰显"数智赋能、万物互 联"的业务定位，与公司当前经营实质高度契合。 为改善经营状况、优化资产质量与财务结构，切实保障中小股东利益，思创医惠于2025年上半年实施重 大资产重组，将智慧医疗板块业务子公司医惠科技100%股权出售给苍南县山海数字科技有限公司，并 于2025年8月完成交割，正式剥离智慧医疗相关业务。 思创医惠相关负责人表示，公司当前已全面推进智慧医疗业务战略收缩，集中资源深耕物联网领域，原 名称中"医惠"二字对应的智慧医疗业务已脱离当前主营业务范畴，无法匹配公司战略转型后的核心定 位，这也是此次更名的重要原因。 在剥离非核心业务的同时，思创医惠正 ...

（编辑 姚尧） 证券日报网讯 12月29日，创业慧康在互动平台回答投资者提问时表示，数据资产的存储不在公司，在 医院客户本身，将来可以通过隐私计算和可信数据空间等技术，搭建价值变现的桥梁，目前公司正通过 将积累的医疗数据产品与AI技术深度融合，帮助客户推动数据资产从"存储"向"服务"与"智能"转变，从 而创造价值。公司利用高质量数据训练和优化AI模型，打造智能产品例如智能临床助手MedCopilot及关 键患者追踪系统APTS等，直接服务于医疗机构客户，实现数据价值的转化。公司亦积极参与国家数据 基础设施建设，构建可信数据生态，在合规前提下探索数据要素的流通与应用。请注意投资风险。 ...

每经头条（nbdtoutiao）——对话马斯克脑机接口"一号受试者"：大脑植入芯片23个月，我正重新夺回 人生的独立 （记者 王晓波） 每经AI快讯，和仁科技（SZ 300550，收盘价：14.06元）12月26日晚间发布公告称，公司第五届第一次 董事会会议于2025年12月26日以现场表决结合通讯表决方式召开。会议审议了《关于选举第五届董事会 董事长的议案》等文件。 2025年1至6月份，和仁科技的营业收入构成为：医疗信息化行业占比96.4%，其他占比3.6%。 截至发稿，和仁科技市值为37亿元。 ...

从资金流向上来看，当日医疗信息化板块主力资金净流出9.99亿元，游资资金净流入2.16亿元，散户资 金净流入7.83亿元。医疗信息化板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，12月26日医疗信息化板块较上一交易日下跌0.07%，荣科科技领跌。当日上证指数报收 于3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。医疗信息化板块个股涨跌见下表： ...

过去，患者在不同医院间就诊时，通常需要自行携带厚重的物理胶片袋，不仅容易丢失或损坏，还有可 能导致不必要的重复检查。为解决这一问题，国家医保局自2024年起推动检查结果跨省互认，医保影像 云工程的核心就是构建一个能让影像数据在全国安全存储、便捷调阅的数字化平台。今年11月，全国跨 省调阅服务启动，部分省份医生在诊室已可实时调阅外地患者的原始影像。该系统的快速推进，得益于 相关价格机制的调整。 本报讯（记者柴嵘）国家医保局昨天介绍，全国医保影像云平台已累计归集医学影像索引数据超过2.5 亿条，这标志着医保影像基础数据 "全国一张网"已经初步建成。 ...

Core Insights - The launch of the national medical insurance imaging cloud for cross-province retrieval aims to enhance the efficiency of medical imaging services and reduce patient costs by minimizing redundant examinations [5][6][7] - The initiative is part of a broader effort to address long-standing issues in healthcare, such as high costs and the inconvenience of repeated tests when patients seek care in different hospitals [6][8] Group 1: Implementation and Benefits - The Jiangsu province has successfully implemented a health cloud imaging platform that allows for the online sharing and mutual recognition of medical imaging results across all public medical institutions [7][8] - By utilizing existing imaging results, it is estimated that redundant examinations could be reduced by nearly 30%, potentially saving over 600 billion yuan in healthcare costs [7][12] - The national medical insurance bureau has introduced guidelines to include digital imaging processing and cloud storage in the pricing of radiological services, promoting the upload of imaging results to the cloud for easier access [7][10] Group 2: Challenges and Solutions - Technical issues such as slow retrieval speeds and varying quality of imaging data across different hospitals have been identified as challenges in the implementation of the imaging cloud [9][10][11] - The national medical insurance bureau is working on solutions to improve data transmission speeds and establish unified standards for imaging quality and data handling [10][11] - The introduction of advanced technologies, such as 6G, is expected to enhance the efficiency of data transmission and address current limitations [10] Group 3: Future Developments - The "cloud film" centralized procurement project in Guizhou is seen as a model for future initiatives, aiming to streamline the storage and processing of medical imaging data while preventing over-medicalization and data fraud [12][14] - By the end of 2025, the goal is to enable cross-institutional access to imaging data in major cities like Beijing, Shanghai, and Guangzhou, with a nationwide integration target set for 2027 [14][15] - As of December 2025, 26 provinces and regions have completed the deployment of medical insurance imaging cloud software, with over 205 million indexing data uploaded to the national medical insurance bureau [14][15]

证券之星消息，12月25日医疗信息化板块较上一交易日上涨0.92%，证通电子领涨。当日上证指数报收 于3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。医疗信息化板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日医疗信息化板块主力资金净流出5.22亿元，游资资金净流出1.67亿元，散户资 金净流入6.89亿元。医疗信息化板块个股资金流向见下表： ...